Barbui T et al. The interaction between IPSS score and JAK2 mutation identifies patients at different vascular risk in primary myelofibrosis. ASH 2021;Abstract 236.
Gerds AT et al. A real-world evaluation of the association between elevated blood counts and thrombotic events in polycythemia vera (analysis of data from the REVEAL study). ASH 2021;Abstract 239.
Gotlib J et al. A phase 2 study of pemigatinib (FIGHT-203; INCB054828) in patients with myeloid/lymphoid neoplasms (MLNs) with fibroblast growth factor receptor 1 (FGFR1) rearrangement (MLNFGFR1). ASH 2021;Abstract 385.
Gupta V et al. Safety and tolerability of fedratinib (FEDR), an oral inhibitor of janus kinase 2 (JAK2), in patients with intermediate- or high-risk myelofibrosis (MF) previously treated with ruxolitinib: Results from the phase 3b FREEDOM trial. ASH 2021;Abstract 389.
Harrison CN et al. Real-world utilization of fedratinib for myelofibrosis post-ruxolitinib: Patient characteristics, treatment patterns, and characterization of ruxolitinib failure. ASH 2021;Abstract 3059.
Hoffman R et al. Rusfertide (PTG-300) controls hematocrit levels and essentially eliminates phlebotomy requirement in polycythemia vera patients. ASH 2021;Abstract 388.
Loscocco GG et al. A JAK2V617F variant allele frequency greater than 50% identifies patients with polycythemia vera at high risk for venous thrombosis. ASH 2021;Abstract 237.
Kiladjian JJ et al. Spleen and symptom responses with fedratinib (FEDR) patients with myelofibrosis (MF) and substantial splenomegaly. ASH 2021;Abstract 2576.
Kremyanskaya M et al. Pelabresib (CPI-0610) monotherapy in patients with myelofibrosis – update of clinical and translational data from the ongoing MANIFEST trial. ASH 2021;Abstract 141.
Mascarenhas J et al. Clinical outcomes at 3 and 6 months of fedratinib therapy following prior ruxolitinib failure: Real-world assessment of spleen, symptoms, and hematologic response. ASH 2021;Abstract 1980.
Mascarenhas J et al. A retrospective head-to-head comparison between pacritinib and ruxolitinib in patients with myelofibrosis and moderate to severe thrombocytopenia. ASH 2021;Abstract 3639.
Mesa RA et al. INDEPENDENCE: A phase 3 study of efficacy and safety of luspatercept versus placebo in patients with myeloproliferative neoplasm-associated myelofibrosis on JAK2 inhibitor therapy and requiring red blood cell transfusions. ASH 2021;Abstract 1490.
Palmer JM et al. The impact of pacritinib on myelofibrosis symptoms in patients with moderate and severe thrombocytopenia: A retrospective analysis of patients in the Persist-2 study. ASH 2021;Abstract 3628.
Passamonti F et al. Real-world outcomes with fedratinib therapy in patients who discontinued ruxolitinib for primary myelofibrosis. ASH 2021;Abstract 3645.
Tefferi A et al. A globally applicable “triple AAA” risk model for essential thrombocythemia based on age, absolute neutrophil count, and absolute lymphocyte count. ASH 2021;Abstract 238.
Verstovsek S et al. Does early intervention in myelofibrosis impact outcomes? A pooled analysis of the Comfort I and II studies. ASH 2021;Abstract 1505.
Yacoub A et al. A randomized, double-blind, placebo-controlled phase 3 study of add-on parsaclisib in patients with myelofibrosis who have suboptimal response to ruxolitinib. ASH 2021;Abstract 1502.
Yacoub A et al. A phase 3, randomized, double-blind, placebo-controlled study of ruxolitinib plus parsaclisib in patients with JAK- and PI3K-inhibitor treatment–naive myelofibrosis. ASH 2021;Abstract 2579.
Yacoub A et al. Subgroup analysis from a phase 2 study of the efficacy and safety of parsaclisib, a selective PI3K-delta inhibitor, in combination with ruxolitinib in patients with myelofibrosis (MF). ASH 2021;Abstract 3647.